Boston Scientific : BSX

All Boston Scientific Articles

262 Articles

Douglas A. McIntyre | Jul 27, 2007 at 6:06 AM EDT

Amgen’s (AMGN) Troubled Quarter

Amgen (AMGN) actually rallied a bit after hours yesterday. But, revenue growth was hard to come by. Amgen reported net…

Douglas A. McIntyre | Jul 20, 2007 at 7:41 AM EDT

Stent Blockage Kills Boston Scientific (BSX)

A large drop in the sale of drug coated stents knocked Boston Scientific’s (BSX) quarter way down. The company’s second-quarter…

Douglas A. McIntyre | Jul 14, 2007 at 7:16 AM EDT

Better Medicine For Boston Scientific (BSX)

Boston Scienfitic (BSX) has a deal to "settle all pending federal lawsuits against the company alleging harm from faulty defibrillators…

Douglas A. McIntyre | Jul 13, 2007 at 5:05 PM EDT

Top Earnings Next Week Part 2 (July 19-20, 2007)

THURSDAYAdvanced Micro Devices (NYSDAQ:AMD)Ameritrade (NASDAQ:AMTD)Bank of America (NYSE:BAC)Bank of New York (NYSE:BK)Cemex (NYSE:CX/ADR)Continental Airlines (NYSE:CAL)Cypress Semi (NYSE:CY)Dow Jones (NYSE:DJ)Fifth Third…

Douglas A. McIntyre | Jul 5, 2007 at 3:12 AM EDT

Media Digest 7/5/2007 Reuters, WSJ, NYTimes, FT, Barron’s

According to Reuters, Australia Australian fund manager Caledonia said it would vote against Chicago Merch’s (CME) proposal to buy CBOT…

Douglas A. McIntyre | Jun 24, 2007 at 12:16 PM EDT

Mixed Short Interest in Drug & Medical Stocks (June 2007)

As you will see, the short interest changes in medical and drug stocks of the active NYSE-listed names was a…

Douglas A. McIntyre | May 22, 2007 at 4:36 PM EDT

Short Selling Up in Drug & Medical Stocks

Some sectors showed mixed results in the short selling, but the Big Pharma and medical instruments and related companies saw…

1 … 16 17 18

Boston Scientific : BSX

All Boston Scientific Articles

Amgen’s (AMGN) Troubled Quarter

Stent Blockage Kills Boston Scientific (BSX)

Better Medicine For Boston Scientific (BSX)

Top Earnings Next Week Part 2 (July 19-20, 2007)

Media Digest 7/5/2007 Reuters, WSJ, NYTimes, FT, Barron’s

Mixed Short Interest in Drug & Medical Stocks (June 2007)

Short Selling Up in Drug & Medical Stocks

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

ISPY’s 0.56% Fee Hides a $38,000 Decade-Long Performance Gap Against SPY

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

Boston Scientific : BSX

All Boston Scientific Articles

Amgen’s (AMGN) Troubled Quarter

Stent Blockage Kills Boston Scientific (BSX)

Better Medicine For Boston Scientific (BSX)

Top Earnings Next Week Part 2 (July 19-20, 2007)

Media Digest 7/5/2007 Reuters, WSJ, NYTimes, FT, Barron’s

Mixed Short Interest in Drug & Medical Stocks (June 2007)

Short Selling Up in Drug & Medical Stocks

NVDL’s 2x Promise Delivered Only 17.21% While NVIDIA Soared 22.21% in One Year

Your 5% CD Is Gone and the Bank’s Renewal Offer Is Insulting. These 3 ETFs Keep Paying After the Fed Stops

ISPY’s 0.56% Fee Hides a $38,000 Decade-Long Performance Gap Against SPY

Featured Reads

How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62

The Portfolio Blueprint for Building $50,000 a Month in Dividend Income